{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:55:26Z","timestamp":1794002126950,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07368-4","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T11:16:14Z","timestamp":1764933374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Narciclasine as a potential therapeutic agent to overcome EGFR-TKI resistance in non-small cell lung cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Jee Young","family":"Sung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha-Eun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soomi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyeun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Eun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Il","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungsil","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Ku","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaegal","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6356-8678","authenticated-orcid":false,"given":"Yong-Nyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"7368_CR1","doi-asserted-by":"crossref","unstructured":"Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25(1):45\u201352.","DOI":"10.5114\/wo.2021.103829"},{"key":"7368_CR2","doi-asserted-by":"crossref","unstructured":"El-Telbany A, Ma PC. Cancer genes in lung cancer: racial disparities: are there any? Genes Cancer. 2012;3(7\u20138):467\u201380.","DOI":"10.1177\/1947601912465177"},{"key":"7368_CR3","doi-asserted-by":"crossref","unstructured":"Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3\u201320.","DOI":"10.1002\/1878-0261.12155"},{"key":"7368_CR4","doi-asserted-by":"crossref","unstructured":"Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958\u201367.","DOI":"10.1056\/NEJMoa0904554"},{"key":"7368_CR5","doi-asserted-by":"crossref","unstructured":"Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118(2):257\u201362.","DOI":"10.1002\/ijc.21496"},{"key":"7368_CR6","doi-asserted-by":"crossref","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497\u2013500.","DOI":"10.1126\/science.1099314"},{"key":"7368_CR7","doi-asserted-by":"crossref","unstructured":"Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305(5687):1163\u201367.","DOI":"10.1126\/science.1101637"},{"key":"7368_CR8","doi-asserted-by":"crossref","unstructured":"Gajiwala KS, Feng J, Ferre R, Ryan K, Brodsky O, Weinrich S, Kath JC, Stewart A. Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure. 2013;21(2):209\u201319.","DOI":"10.1016\/j.str.2012.11.014"},{"key":"7368_CR9","doi-asserted-by":"crossref","unstructured":"Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5(5):390\u2013401.","DOI":"10.1016\/j.apsb.2015.07.001"},{"key":"7368_CR10","doi-asserted-by":"crossref","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357.","DOI":"10.1056\/NEJMoa0810699"},{"key":"7368_CR11","doi-asserted-by":"crossref","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121\u201328.","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"7368_CR12","doi-asserted-by":"crossref","unstructured":"Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.","DOI":"10.1371\/journal.pmed.0020073"},{"key":"7368_CR13","doi-asserted-by":"crossref","unstructured":"Vikis H, Sato M, James M, Wang D, Wang Y, Wang M, Jia D, Liu Y, Bailey-Wilson JE, Amos CI, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res. 2007;67(10):4665\u201370.","DOI":"10.1158\/0008-5472.CAN-07-0217"},{"key":"7368_CR14","doi-asserted-by":"crossref","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337.","DOI":"10.1038\/s41416-019-0573-8"},{"key":"7368_CR15","doi-asserted-by":"crossref","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, et al. Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","DOI":"10.1056\/NEJMoa1913662"},{"key":"7368_CR16","doi-asserted-by":"crossref","unstructured":"Kornienko A. Evidente a: chemistry, biology, and medicinal potential of narciclasine and its congeners. Chem Rev. 2008;108(6):1982\u20132014.","DOI":"10.1021\/cr078198u"},{"key":"7368_CR17","doi-asserted-by":"crossref","unstructured":"Ceriotti G. Narciclasine: an antimitotic substance from narcissus bulbs. Nature. 1967;213(5076):595\u201396.","DOI":"10.1038\/213595a0"},{"key":"7368_CR18","doi-asserted-by":"crossref","unstructured":"Furst R. Narciclasine - an amaryllidaceae alkaloid with potent antitumor and anti-inflammatory properties. Planta Med. 2016;82(16):1389\u201394.","DOI":"10.1055\/s-0042-115034"},{"key":"7368_CR19","doi-asserted-by":"crossref","unstructured":"Gopalakrishnan R, Matta H, Choi S, Chaudhary PM. Narciclasine, an isocarbostyril alkaloid, has preferential activity against primary effusion lymphoma. Sci Rep. 2020;10(1):5712.","DOI":"10.1038\/s41598-020-62690-9"},{"key":"7368_CR20","doi-asserted-by":"crossref","unstructured":"Lefranc F, Sauvage S, Van Goietsenoven G, Megalizzi V, Lamoral-Theys D, Debeir O, Spiegl-Kreinecker S, Berger W, Mathieu V, Decaestecker C, et al. Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Mol Cancer Ther. 2009;8(7):1739\u201350.","DOI":"10.1158\/1535-7163.MCT-08-0932"},{"key":"7368_CR21","doi-asserted-by":"crossref","unstructured":"Shen J, Zhang T, Cheng Z, Zhu N, Wang H, Lin L, Wang Z, Yi H, Hu M. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression. J Exp Clin Cancer Res. 2018;37(1):157.","DOI":"10.1186\/s13046-018-0785-4"},{"key":"7368_CR22","doi-asserted-by":"crossref","unstructured":"Terai H, Soejima K, Yasuda H, Nakayama S, Hamamoto J, Arai D, Ishioka K, Ohgino K, Ikemura S, Sato T, et al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res. 2013;11(7):759\u201367.","DOI":"10.1158\/1541-7786.MCR-12-0652"},{"key":"7368_CR23","doi-asserted-by":"crossref","unstructured":"Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 2015;111:A3 1\u20133 3.","DOI":"10.1002\/0471142735.ima03bs111"},{"key":"7368_CR24","doi-asserted-by":"crossref","unstructured":"Ishiyama M, Shiga M, Sasamoto K, Mizoguchi M. He P-G. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull (Tokyo). 1993;41(6):1118\u201322.","DOI":"10.1248\/cpb.41.1118"},{"key":"7368_CR25","doi-asserted-by":"crossref","unstructured":"Tam IY, Leung EL, Tin VP, Chua DT, Sihoe AD, Cheng LC, Chung LP, Wong MP. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther. 2009;8(8):2142\u201351.","DOI":"10.1158\/1535-7163.MCT-08-1219"},{"key":"7368_CR26","doi-asserted-by":"crossref","unstructured":"Feng Y, Dai X, Li X, Wang H, Liu J, Zhang J, Du Y, Xia L. EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis. Cell Prolif. 2012;45(5):413\u201319.","DOI":"10.1111\/j.1365-2184.2012.00837.x"},{"key":"7368_CR27","doi-asserted-by":"crossref","unstructured":"Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 2017;9(5).","DOI":"10.3390\/cancers9050052"},{"key":"7368_CR28","doi-asserted-by":"crossref","unstructured":"Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220\u201327.","DOI":"10.1038\/sj.onc.1209615"},{"key":"7368_CR29","doi-asserted-by":"crossref","unstructured":"Clayton AL, Mahadevan LC. Map kinase-mediated phosphoacetylation of histone H3 and inducible gene regulation. FEBS Lett. 2003;546(1):51\u201358.","DOI":"10.1016\/S0014-5793(03)00451-4"},{"key":"7368_CR30","doi-asserted-by":"crossref","unstructured":"Choi HS, Choi BY, Cho YY, Mizuno H, Kang BS, Bode AM, Dong Z. Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res. 2005;65(13):5818\u201327.","DOI":"10.1158\/0008-5472.CAN-05-0197"},{"key":"7368_CR31","doi-asserted-by":"crossref","unstructured":"Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor\/extracellular signal-regulated kinase 1\/2 and EGF receptor\/Akt pathway for proliferation. Mol Cancer Ther. 2004;3(4):465\u201372.","DOI":"10.1158\/1535-7163.465.3.4"},{"key":"7368_CR32","doi-asserted-by":"crossref","unstructured":"He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd\u2011generation EGFR\u2011TKI resistance in advanced non\u2011small cell lung cancer (Review). Int J Oncol. 2021;59(5).","DOI":"10.3892\/ijo.2021.5270"},{"key":"7368_CR33","doi-asserted-by":"crossref","unstructured":"Liu Z, Ma L, Sun Y, Yu W, Wang X. Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer. Cell Death Dis. 2021;12(6):561.","DOI":"10.1038\/s41419-021-03844-z"},{"key":"7368_CR34","doi-asserted-by":"crossref","unstructured":"Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, et al. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin Cancer Res. 2014;20(15):4059\u201374.","DOI":"10.1158\/1078-0432.CCR-13-1559"},{"key":"7368_CR35","doi-asserted-by":"crossref","unstructured":"Remon J, Steuer CE, Ramalingam SS. Felip E: osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. 2018;29(suppl_1):i20\u201327.","DOI":"10.1093\/annonc\/mdx704"},{"key":"7368_CR36","doi-asserted-by":"crossref","unstructured":"Bae YK, Sung JY, Kim YN, Kim S, Hong KM, Kim HT, Choi MS, Kwon JY, Shim J. An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs. PLoS One. 2012;7(9):e42441.","DOI":"10.1371\/journal.pone.0042441"},{"key":"7368_CR37","doi-asserted-by":"crossref","unstructured":"Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014;24(1):26\u201334.","DOI":"10.1016\/j.tcb.2013.11.002"},{"key":"7368_CR38","doi-asserted-by":"crossref","unstructured":"Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A. 1986;83(11):3825\u201329.","DOI":"10.1073\/pnas.83.11.3825"},{"key":"7368_CR39","doi-asserted-by":"crossref","unstructured":"Okada Y, Kimura T, Nakagawa T, Okamoto K, Fukuya A, Goji T, Fujimoto S, Sogabe M, Miyamoto H, Muguruma N, et al. EGFR downregulation after anti-EGFR therapy predicts the antitumor effect in colorectal cancer. Mol Cancer Res. 2017;15(10):1445\u201354.","DOI":"10.1158\/1541-7786.MCR-16-0383"},{"key":"7368_CR40","doi-asserted-by":"crossref","unstructured":"Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol. 2003;194(1):13\u201319.","DOI":"10.1002\/jcp.10194"},{"key":"7368_CR41","doi-asserted-by":"crossref","unstructured":"Pedersen MW, Pedersen N, Ottesen LH, Poulsen HS. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005;93(8):915\u201323.","DOI":"10.1038\/sj.bjc.6602793"},{"key":"7368_CR42","doi-asserted-by":"crossref","unstructured":"Tsien CI, Nyati MK, Ahsan A, Ramanand SG, Chepeha DB, Worden FP, Helman JI, D\u2019Silva N, Bradford CR, Wolf GT, et al. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. Head Neck. 2013;35(9):1323\u201330.","DOI":"10.1002\/hed.23128"},{"key":"7368_CR43","doi-asserted-by":"crossref","unstructured":"Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(13):3908\u201314.","DOI":"10.1158\/1078-0432.CCR-06-0462"},{"key":"7368_CR44","doi-asserted-by":"crossref","unstructured":"Lv C, Huang Y, Huang R, Wang Q, Zhang H, Jin J, Lu D, Zhou Y, Shen Y, Zhang W, et al. Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells. Mol Ther Oncolytics. 2022;24:340\u201354.","DOI":"10.1016\/j.omto.2021.12.025"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07368-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07368-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07368-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T11:16:18Z","timestamp":1764933378000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07368-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7368"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07368-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"This study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of National Cancer Center Research Institute (NCCRI). NCCRI is an Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International) accredited facility and abides by the Institute of Laboratory Animal Resources (ILAR) guide.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors state no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1380"}}